Pharmacielo Ltd. · TSXV:PCLO
Pharmacielo — Investor Presentation (January 2019)
21 slides from Pharmacielo's investor presentation, January 2019
Slide 1: PharmaCielo - January 2019
a PharmaCielo Nature's Choice From Colombia ae ae January 2019 | TSXV: PCLO e < ies ae ——— eee: th rn =
Slide 2: Disclaimer and Cautionary Note Regarding Forward-Looking Statements
Disclaimer and Cautionary Note Regarding Forward-Looking Statements Disclaimer and Cautionary Note Regarding Forward-Looking Statements This presentation (“Presentation”) contains information regarding PharmaCielo Ltd. (the “Company”, “we”, “us” or “our”). Under no circumstances may the contents of
Slide 3: Large CPG and Pharma Companies are Developing Cannabis Strategies
Large CPG and Pharma Companies are Developing Cannabis Strategies Beverage Chemicals Alcohol Wellness & Beauty Pharmaceutical Tobacco 3
Slide 4: Winning Producers Must Offer
WINNING PRODUCERS MUST OFFER: Reliability of Supply Consistency of Product Customization of Extract The biggest CPG manufacturers need unique, quality inputs at scale 4
Slide 5: Built to Supply Global End-Product Companies and Distributors
BUILT TO SUPPLY THE WORLD’S GLOBAL END- PRODUCT COMPANIES & LARGE CHANNEL DISTRIBUTORS WITH MEDICAL GRADE CANNABINOID EXTRACTS 5
Slide 6: Expertise Necessary to Build Global Cannabis Supplier
Expertise Necessary to Build Global Cannabis Supplier Engaged Board and Knowledgeable Management: Technical, Cultivation, and General Enterprise Experience Technical Cultivation General Enterprise 100+ years of medical and chemical 100+ years of managing large-scale 200+ years of senior leadership i
Slide 7: Colombia: An agricultural powerhouse
Colombia: An agricultural powerhouse 2nd largest supplier 3rd largest supplier 5th largest supplier of cut flowers of coffee of bananas Colombia is committed to becoming the world’s leading supplier of cannabis extracts 7
Slide 8: Colombia: Structural Cost Advantage
Colombia: Structural Cost Advantage Ideal Natural Conditions • One of only a few places globally where you can efficiently grow cannabis • Natural & consistent 12-hour light cycle and temperate climate means: • Minimal energy costs • Extremely low carbon footprint • High production efficiency • Natu
Slide 9: Licensed and Operational Today
Licensed and Operational Today Licensing Regime Genetic Registration 1. Cannabis Breeding Program ✓ • 30 strains registered for commercial production as 2. Authorized Seed Distributor ✓ of February 2019 3. Cannabis Psychoactive Cultivation Licence ✓ • 186 strains registered in PharmaCielo germplasm
Slide 10: Highly Scalable Business Model
Highly Scalable Business Model Company-Owned and Cultivation Facilities Under Contract: Nursery & Propagation 12 Hectares 0.48 Million KG1 open-air greenhouses flower capacity per year Company-Owned with 4 Hectares 0.15 Million KG Indigenous Growers open-air greenhouses flower capacity per year Cont
Slide 11: Oil Extraction Phase One
Oil Extraction Phase One 2,300 m2 full-scale production facility (complete by Q2 2019) 12 metric tonnes of refined cannabis oil capacity per year GMP certification expected by Q3 2019 ISO 9001 pre-audit complete Building inventory for 2019 market distribution 11
Slide 12: Increasing Production Capacity
Increasing Production Capacity By the end of 2019 we expect to: have our GMP certified production have 20 hectares planted. facility completed. Capable of 12 metric tonnes of cannabis oil a year. 12
Slide 13: Growth Strategy
= PharmaCielo Nature's Choice From Colombia Growth Strategy
Slide 14: Strategic Approach to Long-Term Growth
Strategic Approach to Long-Term Growth Branded Products Sales Channel Opportunities Global Market Co-Branding PharmaCielo Inside High-grade oil for large channel distributors, pharma, and CPG companies Bulk CBD & THC Oil Europe, Canada, and South America Today Long-Term Margin expansion as we move u
Slide 15: Assisting Medical Practitioners in Accessing Cannabinoid Medicinal Treatments
Assisting Medical Practitioners in Accessing Cannabinoid Medicinal Treatments • Launched Colombia’s first certified 1 training program in medicinal cannabis with the Universidad CES medical school, Colombia’s premier medical school. • 100% ownership of Colombia’s only patient & e-clinic platform • O
Slide 16: Near-Term Target Markets
Near-Term Target Markets Global Expansion Under Development Colombia Mexico Uruguay Italy Canada Argentina PharmaCielo expects to forge partnership in at least two markets in 2019 16
Slide 17: Corporate Overview
fF PharmaCielo Nature's Choice From Colombia
Slide 18: Capital Structure
Capital Structure1 Shares Outstanding: 94.0 Million Fully Diluted S/O: 110.5 Million Recent Price: CDN$3.35 Fully Diluted Market Cap: CDN$370.18 Cash: CDN$41.4 Million2 Insider Ownership: ~20% 1) As of Listing Statement, January 9, 2019 2) Converted to CAD at $1.32 as of January 9, 2019 18
Slide 19: Management Team: Experience + Expertise
Management Team: Experience + Expertise David Attard: CEO, Director Dr. Delon Human: Global Head of Health and Innovation • Former Senior Vice President, Corporate Strategy & Business • Dr. Human, MBChB, MPraxMed, MFGP, DCH, MBA is a published author, Innovation and member of the Executive Managemen
Slide 20: Non-Executive Board Members
Non-Executive Board Members Simon Langelier, Chairman of the Board Carlos Manuel Uribe, Chairman of the Board, • Served in leadership capacities with Philip Morris International (PMI) PharmaCielo Colombia and subsidiaries for over 30 years, most recently as the managing • Served since 2000 as genera
Slide 21: PharmaCielo - January 2019
a PharmaCielo Nature's Choice From Colombia January 2019 | TSXV: PCL —— 21